abstract |
Novel bifunctional peptides useful in the treatment and/or diagnosis of EAE or MS. The peptides have a first peptide portion derived from an epitope of myelin proteolipid protein, myelin oligodendrocyte glycoprotein, or oligodendrocyte-specific peptide and a second peptide portion derived from CD11a (LFA-1 alpha subunit), CD18 (LFA-1 beta subunit), CD154 (CD40L), Fas-Ligand. or CTLA4. The carboxy and/or amino termini of the bifunctional peptides may be modified. |